Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Breast cancers is an uncontrolled growth of cancerous breast tissue. Melanoma occurs because of mutations, or uncommon changes, inside the genes accountable for controlling the expansion of cellular material in addition to maintaining healthy cells. The genes are usually in each and every cells' nucleus, which often acts as the control room of each cell. Usually, the cells in our bodies exchange on their own through an orderly procedure for cell growth: healthy completely new cells take over as old ones die away. But over time, malignant strains might "turn on" certain genes and "turn off" others in a cell. The transformed cell gains the opportunity to continue splitting without regulation or order, producing additional cells similar to them along with building a tumor.
Alzheimer's is among one of the well known forms of dementia. Alzheimer's is a standard term for loss of memory along with other cerebral abilities major enough to obstruct an individuals daily routine. Alzheimer's is liable for 50% to 70% of dementia cases.
Alzheimer's is not an everyday part of growing older, although the most significant known risk factor is increasing age, and most people with Alzheimer's are 65 and older. But Alzheimer's is not merely a sickness associated with aging. As much as a few percent of people with the actual illness possess early-onset Alzheimer's (also referred to as younger-onset), which regularly appears when someone is within their 40's or 50's.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” stated Dr. Ira L. Goldknopf, PWRM’s President & Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
To learn more about PWRM visit: http://www.Power3Medical.com
Ediets.com Inc. (Nasdaq:DIET) - Elizabeth and Patrick, "Biggest Loser" finalists, have been using The Biggest Loser Meal Plan by eDiets at home to help ensure they get the right nutrition and calories to lose weight in time for the season finale and win the $250,000 prize. The Biggest Loser Meal Plan by eDiets is licensed through NBC Universal Television Consumer Products Group and Reveille LLC. The convenience of having the nutritious, calorie-controlled meals delivered to their door is a significant benefit for these contestants. "I don't have to stare at my cabinets trying to figure out what to eat. I don't have to weigh food or measure," Patrick said. "It's quick; it's simple; it's awesome and I know exactly the nutrition that I'm putting into my body."
eDiets.com, Inc. engages in developing and marketing Internet-based diet and fitness programs to consumers and businesses primarily in North America. It offers various digital subscription-based diet plans according to an individual’s weight goals, food and cooking preferences, and related shopping lists and recipes; and subscription-based weight loss oriented meal delivery services, as well as interactive online information, communities, education, and telephone and online support services.****************************
Vision-Sciences Inc. (Nasdaq:VSCI) announced this week that its Board of Directors elected Dr. Bruce Polsky to serve as a member of its Board, effective immediately. Dr. Polsky will be an independent member of the Board. "I am extremely pleased to welcome Bruce to the Board. His extensive medical background and knowledge of infectious diseases add significantly to our organization," said Lewis Pell, Chairman of Vision-Sciences. Dr. Polsky was elected as a Class II director, to serve until Vision-Sciences' 2011 annual shareholders' meeting. Dr. Polsky was nominated to be reelected to the Board at Vision-Sciences' annual shareholders' meeting, expected to be held in September 2011.
Vision-Sciences, Inc. designs, develops, manufactures, and markets products for endoscopy. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, and sells a line of endoscopy-based products, including flexible endoscopes and sheath or EndoSheath disposables primarily to the ENT, urology, gastroenterology, and pulmonology markets.
Coldwater Creek Inc. (Nasdaq:CWTR) reported financial results for the three- and nine-month periods ended October 30, 2010. Net sales were $232.4 million, compared with $266.7 million in the fiscal 2009 third quarter. Net sales from the retail segment, which includes the Company's premium retail stores, outlet stores and day spa locations, decreased 15.9 percent to $174.3 million, versus $207.3 million in the same period last year, primarily reflecting a decrease in comparable premium retail store sales of 20.1 percent. Gross profit for the fiscal 2010 third quarter was $70.9 million, or 30.5 percent of net sales, compared with $97.1 million, or 36.4 percent of net sales, for the fiscal 2009 third quarter.
Coldwater Creek Inc., together with its subsidiaries, operates as a multi-channel specialty retailer of women's apparel, accessories, jewelry, and gift items primarily in the United States. It operates premium retail stores and merchandise clearance outlet stores; and day spas, which offer various spa treatments, including massages, facials, body treatments, manicures, and pedicures, as well as an assortment of relevant apparel and lines of personal care products for women.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).